{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:29:17Z","timestamp":1758706157489,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010904","name":"Major International Joint Research Programme","doi-asserted-by":"crossref","award":["81820108004"],"award-info":[{"award-number":["81820108004"]}],"id":[{"id":"10.13039\/501100010904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81700137"],"award-info":[{"award-number":["81700137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12032-019-1302-0","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T17:02:51Z","timestamp":1564678971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells"],"prefix":"10.1007","volume":"36","author":[{"given":"Jingrui","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"1","key":"1302_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41588-018-0270-1","volume":"51","author":"SA Assi","year":"2018","unstructured":"Assi SA, Imperato MR, Coleman DJL, Pickin A, Potluri S, Ptasinska A, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet. 2018;51(1):151\u201362. \n                    https:\/\/doi.org\/10.1038\/s41588-018-0270-1\n                    \n                  .","journal-title":"Nat Genet"},{"issue":"4","key":"1302_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016;66(4):271\u201389. \n                    https:\/\/doi.org\/10.3322\/caac.21349\n                    \n                  .","journal-title":"CA: a cancer journal for clinicians"},{"issue":"13","key":"1302_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249\u201359. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0904544\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"9865","key":"1302_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","volume":"381","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484\u201395. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61727-9\n                    \n                  .","journal-title":"Lancet"},{"issue":"3","key":"1302_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453\u201374. \n                    https:\/\/doi.org\/10.1182\/blood-2009-07-235358\n                    \n                  .","journal-title":"Blood"},{"issue":"23","key":"1302_CR6","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","volume":"130","author":"AH Wei","year":"2017","unstructured":"Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017;130(23):2469\u201374. \n                    https:\/\/doi.org\/10.1182\/blood-2017-08-784066\n                    \n                  .","journal-title":"Blood"},{"issue":"5","key":"1302_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487\u201394. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.30.1820\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"12","key":"1302_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079\u201389. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112304\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"3","key":"1302_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jamaoncol.2016.3928","volume":"3","author":"JG Jurcic","year":"2017","unstructured":"Jurcic JG. Highlights in hematologic malignancy treatments: leukemia, myelodysplastic syndromes, and allotransplant-new drugs on the horizon for acute myeloid leukemia. JAMA Oncol. 2017;3(3):299\u2013300. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.3928\n                    \n                  .","journal-title":"JAMA Oncol"},{"issue":"25","key":"1302_CR10","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.2174\/092986712802884286","volume":"19","author":"M Stiborova","year":"2012","unstructured":"Stiborova M, Eckschlager T, Poljakova J, Hrabeta J, Adam V, Kizek R, et al. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem. 2012;19(25):4218\u201338.","journal-title":"Curr Med Chem"},{"issue":"5","key":"1302_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2165\/00003495-200161050-00009","volume":"61","author":"JA Balfour","year":"2001","unstructured":"Balfour JA, Goa KL. Bendamustine. Drugs. 2001;61(5):631\u20138. \n                    https:\/\/doi.org\/10.2165\/00003495-200161050-00009\n                    \n                   (Discussion 9\u201340).","journal-title":"Drugs"},{"issue":"5","key":"1302_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1188\/08.CJON.799-806","volume":"12","author":"S Blumel","year":"2008","unstructured":"Blumel S, Goodrich A, Martin C, Dang NH. Bendamustine: a novel cytotoxic agent for hematologic malignancies. Clin J Oncol Nurs. 2008;12(5):799\u2013806. \n                    https:\/\/doi.org\/10.1188\/08.CJON.799-806\n                    \n                  .","journal-title":"Clin J Oncol Nurs."},{"issue":"14","key":"1302_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2165\/11209510-000000000-00000","volume":"72","author":"SM Hoy","year":"2012","unstructured":"Hoy SM. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin\u2019s lymphoma and multiple myeloma. Drugs. 2012;72(14):1929\u201350. \n                    https:\/\/doi.org\/10.2165\/11209510-000000000-00000\n                    \n                  .","journal-title":"Drugs"},{"issue":"1","key":"1302_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd2227","volume":"6","author":"S Grant","year":"2007","unstructured":"Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov. 2007;6(1):21\u20132. \n                    https:\/\/doi.org\/10.1038\/nrd2227\n                    \n                  .","journal-title":"Nat Rev Drug Discov"},{"issue":"46","key":"1302_CR15","doi-asserted-by":"publisher","first-page":"28155","DOI":"10.18632\/oncotarget.25588","volume":"9","author":"Y Qiu","year":"2018","unstructured":"Qiu Y, Li Z, Copland JA, Mehrling T, Tun HW. Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. Oncotarget. 2018;9(46):28155\u201364. \n                    https:\/\/doi.org\/10.18632\/oncotarget.25588\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"1","key":"1302_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-018-0576-6","volume":"11","author":"C Festuccia","year":"2018","unstructured":"Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, et al. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018;11(1):32. \n                    https:\/\/doi.org\/10.1186\/s13045-018-0576-6\n                    \n                  .","journal-title":"J Hematol Oncol"},{"issue":"24","key":"1302_CR17","doi-asserted-by":"publisher","first-page":"20121","DOI":"10.18632\/oncotarget.4041","volume":"6","author":"J Yu","year":"2015","unstructured":"Yu J, Qiu S, Ge Q, Wang Y, Wei H, Guo D, et al. A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells. Oncotarget. 2015;6(24):20121\u201331. \n                    https:\/\/doi.org\/10.18632\/oncotarget.4041\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"1","key":"1302_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-017-0495-y","volume":"10","author":"AA Lopez-Iglesias","year":"2017","unstructured":"Lopez-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, Gonzalez-Mendez L, Hernandez-Garcia S, et al. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. J Hematol Oncol. 2017;10(1):127. \n                    https:\/\/doi.org\/10.1186\/s13045-017-0495-y\n                    \n                  .","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1302_CR19","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1038\/bcj.2017.69","volume":"7","author":"L Besse","year":"2017","unstructured":"Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, et al. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J. 2017;7(7):e589. \n                    https:\/\/doi.org\/10.1038\/bcj.2017.69\n                    \n                  .","journal-title":"Blood Cancer J"},{"issue":"1","key":"1302_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1871520615666150518092027","volume":"16","author":"T Mehrling","year":"2016","unstructured":"Mehrling T, Chen Y. The alkylating-HDAC inhibition fusion principle: taking chemotherapy to the next level with the first in class molecule EDO-S101. Anticancer Agents Med Chem. 2016;16(1):20\u20138.","journal-title":"Anticancer Agents Med Chem"},{"key":"1302_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0065-230X(08)60703-4","volume":"72","author":"S Grant","year":"1998","unstructured":"Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res. 1998;72:197\u2013233.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"1302_CR22","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41467-017-01834-4","volume":"8","author":"A Di Tullio","year":"2017","unstructured":"Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017;8(1):1679. \n                    https:\/\/doi.org\/10.1038\/s41467-017-01834-4\n                    \n                  .","journal-title":"Nat Commun"},{"issue":"4","key":"1302_CR23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.V99.4.1373","volume":"99","author":"MJ Veuger","year":"2002","unstructured":"Veuger MJ, Heemskerk MH, Honders MW, Willemze R, Barge RM. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood. 2002;99(4):1373\u201380.","journal-title":"Blood"},{"issue":"11","key":"1302_CR24","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.3390\/cancers10110414","volume":"10","author":"R M\u2019Kacher","year":"2018","unstructured":"M\u2019Kacher R, Frenzel M, Al Jawhari M, Junker S, Cuceu C, Morat L, et al. Establishment and characterization of a reliable xenograft model of hodgkin lymphoma suitable for the study of tumor origin and the design of new therapies. Cancers. 2018;10(11):E414. \n                    https:\/\/doi.org\/10.3390\/cancers10110414\n                    \n                  .","journal-title":"Cancers"},{"issue":"3","key":"1302_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3324\/haematol.2018.197368","volume":"104","author":"F Koczian","year":"2018","unstructured":"Koczian F, Naglo O, Vomacka J, Vick B, Servatius P, Zisis T, et al. Targeting the ER-mitochondria interface sensitizes leukemia cells towards cytostatics. Haematologica. 2018;104(3):546\u201355. \n                    https:\/\/doi.org\/10.3324\/haematol.2018.197368\n                    \n                  .","journal-title":"Haematologica"},{"issue":"1","key":"1302_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3324\/haematol.10279","volume":"92","author":"U Testa","year":"2007","unstructured":"Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92(1):81\u201394.","journal-title":"Haematologica"},{"issue":"17","key":"1302_CR27","first-page":"3976","volume":"53","author":"SH Kaufmann","year":"1993","unstructured":"Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53(17):3976\u201385.","journal-title":"Cancer Res"},{"issue":"9","key":"1302_CR28","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/0008-5472.CAN-14-2486","volume":"75","author":"C Yang","year":"2015","unstructured":"Yang C, Boyson CA, Di Liberto M, Huang X, Hannah J, Dorn DC, et al. CDK4\/6 Inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity. Cancer Res. 2015;75(9):1838\u201345. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2486\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"1","key":"1302_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hon.2191","volume":"34","author":"O Wolach","year":"2016","unstructured":"Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, et al. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia\u2014is more better or more of the same? Hematol Oncol. 2016;34(1):28\u201335. \n                    https:\/\/doi.org\/10.1002\/hon.2191\n                    \n                  .","journal-title":"Hematol Oncol"},{"issue":"4","key":"1302_CR30","first-page":"759","volume":"7","author":"PA Marks","year":"2001","unstructured":"Marks PA, Rifkind RA, Richon VM, Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res. 2001;7(4):759\u201360.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1302_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06772.x","volume":"139","author":"R Feng","year":"2007","unstructured":"Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 2007;139(3):385\u201397. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06772.x\n                    \n                  .","journal-title":"Br J Haematol"},{"issue":"1","key":"1302_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/0008-5472.CAN-03-2630","volume":"64","author":"K Camphausen","year":"2004","unstructured":"Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004;64(1):316\u201321.","journal-title":"Cancer Res"},{"issue":"13","key":"1302_CR33","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","volume":"11","author":"A Munshi","year":"2005","unstructured":"Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005;11(13):4912\u201322. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2088\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1302_CR34","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1073\/pnas.78.5.3235","volume":"78","author":"PP Major","year":"1981","unstructured":"Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci USA. 1981;78(5):3235\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1302_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16(1):20\u201333. \n                    https:\/\/doi.org\/10.1038\/nrc.2015.2\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"1302_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0960-9822(00)00610-2","volume":"10","author":"TT Paull","year":"2000","unstructured":"Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000;10(15):886\u201395.","journal-title":"Curr Biol"},{"issue":"12","key":"1302_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/ncb884","volume":"4","author":"O Fernandez-Capetillo","year":"2002","unstructured":"Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol. 2002;4(12):993\u20137. \n                    https:\/\/doi.org\/10.1038\/ncb884\n                    \n                  .","journal-title":"Nat Cell Biol"},{"issue":"5625","key":"1302_CR38","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1126\/science.1083430","volume":"300","author":"L Zou","year":"2003","unstructured":"Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003;300(5625):1542\u20138. \n                    https:\/\/doi.org\/10.1126\/science.1083430\n                    \n                  .","journal-title":"Science"},{"issue":"6811","key":"1302_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/35044005","volume":"408","author":"BB Zhou","year":"2000","unstructured":"Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433\u20139. \n                    https:\/\/doi.org\/10.1038\/35044005\n                    \n                  .","journal-title":"Nature"},{"key":"1302_CR40","first-page":"5016","volume":"13","author":"Y Chen","year":"2008","unstructured":"Chen Y, Poon RY. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci. 2008;13:5016\u201329.","journal-title":"Front Biosci"},{"issue":"20","key":"1302_CR41","doi-asserted-by":"publisher","first-page":"11289","DOI":"10.1073\/pnas.191557598","volume":"98","author":"A Lopez-Girona","year":"2001","unstructured":"Lopez-Girona A, Tanaka K, Chen XB, Baber BA, McGowan CH, Russell P. Serine-345 is required for Rad3-dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast. Proc Natl Acad Sci USA. 2001;98(20):11289\u201394. \n                    https:\/\/doi.org\/10.1073\/pnas.191557598\n                    \n                  .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"1302_CR42","doi-asserted-by":"publisher","first-page":"16102","DOI":"10.1074\/jbc.M111705200","volume":"277","author":"T O\u2019Neill","year":"2002","unstructured":"O\u2019Neill T, Giarratani L, Chen P, Iyer L, Lee CH, Bobiak M, et al. Determination of substrate motifs for human Chk1 and hCds1\/Chk2 by the oriented peptide library approach. J Biol Chem. 2002;277(18):16102\u201315. \n                    https:\/\/doi.org\/10.1074\/jbc.M111705200\n                    \n                  .","journal-title":"J Biol Chem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1302-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1302-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1302-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:05:22Z","timestamp":1596153922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1302-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1302-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"8 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consents were acquired from patients according to institutional guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"77"}}